Mission
At Sling, we’re on a mission is to bring patients with thyroid eye disease effective, convenient treatment.
Pipeline
Our lead pipeline program, linsitinib, is in development as the only late-stage oral therapy for the treatment of thyroid eye disease.
Leadership
We have an experienced team of executives, drug developers, and advisors whose deep expertise and dedication keep them driving for solutions.
News
- Sling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Disease
- Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease
- Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer